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CD33 is a cell surface glycoprotein expressed on cells of myelomonocytic lineage, leukaemic cells, but not haematopoietic
stem cells. By virtue of its expression pattern, CD33 has become a popular target for new immunotherapeutic approaches to treat
acute myeloid leukaemia. The methylotrophic yeast Pichia pastoris strain KM71Hwas used to produce an anti-CD33 single chain
variable fragment (scFv), with the intention of conjugation to a radioisotope, for therapeutic use. To direct secreted expression of
the anti-CD33-scFv the a-mating factor secretory signal sequence (a-MF) was used, with constructs containing a complete (CS)
and incomplete (INCS) cleavage site to accommodate the potential outcomes of dibasic endopeptidase, Kex2, and dipeptidyl
amino peptidase, Ste13, processing. The anti-CD33-scFv was expressed in BMMY cultures using both constructs, with a final
yield of 48mg/l (CS) and 11mg/l (INCS). N-terminal sequencing showed that the CS-scFv had not been cleaved by Ste13, leaving
amino acids EAEA at the N-terminus. The INCS-scFv construct produced a mixture of 50% authentic scFv and 50% with 11
amino acids from the a-MF remaining at the N-terminus. Despite the aberrations in a-MF processing, the anti-CD33-scFv’s
produced from both constructs were found to be functional. Flow cytometry and Biacore analysis demonstrated binding to target
antigen CD33 on the surface of human leukaemic cell line HL-60, and to recombinant soluble CD33 respectively.
D 2005 Elsevier B.V. All rights reserved.
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CD33 is a 67 kDa transmembrane glycoprotein
(Simmons and Seed, 1988) with Ig like extracellular
domains and a binding specificity for sialic acid,
features that place it in the structurally related
group of sialic acid binding Ig related lectins (Free-
man et al., 1995; Kelm et al., 1996). CD33 was
originally defined in studies with the monoclonal
antibody MY9 (Griffin et al., 1984), and with addi-
tional studies using antibodies of the CD33 cluster
group (MY9, L1B2, L4F3, WM-53, and WM-54)
showing that CD33 is an early myeloid differentiation
antigen, expressed on colony forming progenitor cells,
such as multipotential stem cells (CFU-GEMM),
granulocyte, macrophage and erythroid precursors
(CFU-GM, BFU-E) (Griffin and Schlossman, 1984;
Andrews et al., 1983; Peiper et al., 1988; Favaloro et
al., 1987). Expression of CD33 continues along the
myelomonocytic pathway until it is downregulated on
granulocytes but retained on monocytes and tissue
macrophages. Although the function of CD33 has
not yet been elucidated, the expression pattern of
CD33 and observations from a number of studies
suggest that CD33 plays a regulatory role in myeloid
cell differentiation/haematopoiesis (Taylor et al.,
1999; Paul et al., 2000; Ulyanova et al., 1999; Mingari
et al., 2001). CD33 is also expressed by leukaemic
blast cells with a density of approximately 10,000
sites per cell (Tanimoto et al., 1989) in 70–90% of
acute myeloid leukaemia (AML) patients, and is con-
sidered a phenotypic marker for AML, particularly
those in the FAB M1–5 classification, where it is
consistently expressed (Griffin et al., 1984; Litz and
Brunning, 1992; Matutes et al., 1985; Dinndorf et al.,
1986). It is, however, not expressed by any non-
haematopoietic cells (Peiper et al., 1989) or the plu-
ripotent haematopoietic stem cells (Bernstein et al.,
1994; Andrews et al., 1989), responsible for the re-
generation of all cells of the haematopoietic system,
and therefore has become a popular target for new
immunotherapies of AML.
A number of anti-CD33 antibodies (Abs) have
already been developed as potential immunotherapeu-
tic agents for AML, used alone (Gibson, 2002; Caron
et al., 1998) or infused with cytokines (Caron et al.,
1995; Kossman et al., 1999), conjugated to radioiso-
topes (Jurcic et al., 1995, 2002), immunotoxins(Pagliaro et al., 1998), other antibodies (bispecific
Abs) (Balaian and Ball, 2001) and most successfully
to the anti-tumour antibiotic calicheamicin, known as
Mylotargk (Tomblyn and Tallman, 2003). These
therapies have concentrated on the use of whole IgG
molecules, whereas increasingly, smaller engineered
antibody fragments such as the single-chain variable
fragments (scFv) are being developed for a number of
applications such as: tumour imaging (Begent et al.,
1996; Goel et al., 2001), cancer therapy (Kikuchi et
al., 2004; Tur et al., 2003), molecular immunolabel-
ling (Malecki et al., 2002), and diagnostics (Peipp et
al., 2004).
Single-chain Abs are composed of a variable
heavy and light chain joined by a small flexible
linker peptide such as (Gly4Ser)3, a structure that
retains the original specificity and full monovalent
binding of the intact parent Ab (Huston et al.,
1998). The smaller size of 25–30 kDa compared
to ~155 kDa of whole IgG Abs confers pharmaco-
kinetic advantages such as faster uptake and better
penetration through the vasculature of tumours
(Yokota et al., 1992). Single-chain Fv proteins ad-
ministered intravenously also have a shorter elimi-
nation time than whole IgG (Colcher et al., 1990),
thereby decreasing the non-specific toxicity to nor-
mal tissues/organs associated with the prolonged
time in circulation of whole IgG. A shorter elimi-
nation time results in high tumour to whole body
uptake ratios, which is particularly important when
using radiolabelled Abs since increased circulation
time exposes normal tissues to an increased radia-
tion dose (Waldmann, 1991; Colcher et al., 1999).
Other scFv advantages include little or no immuno-
genicity, high stability and simplified design of ge-
netically modified constructs for expression of scFv
in a range of systems (Bird et al., 1988; Huston et
al., 1998; Begent et al., 1996).
In this report we describe the use of Pichia pastoris
to express an anti-CD33-scFv, with a view to conju-
gating the scFv to a radioisotope as a possible immu-
notherapeutic approach to treat AML. Since the use of
P. pastoris to produce bsingle-cell-proteinQ by Philips
Petroleum company in the 1980s (Wegner, 1990),
many recombinant proteins have been successfully
expressed (Cereghino and Cregg, 2000) including
other scFv and therapeutic proteins such as anti-desi-
pramine (DMI) scFv for the treatment of DMI over-
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tumour associated glycoprotein TAG-72 (Goel et al.,
2000b). P. pastoris is a methylotrophic yeast whose
ability to utilize methanol as a sole carbon source (Lee
and Komagata, 1980; Ogata et al., 1969) has been
exploited for the expression of recombinant proteins.
The enzyme, alcohol oxidase (AOX), which catalyses
the first step in the methanol utilisation pathway, is
largely encoded by the methanol regulated/inducible
AOX1 gene (Cregg et al., 1989; Ellis et al., 1985). The
AOX1 promoter has been used in many P. pastoris
expression vectors and thus recombinant protein genes
placed downstream and under the control of the AOX1
promoter are transcribed upon addition of methanol to
the expression culture. The highly inducible nature of
protein expression in P. pastoris combined with the
ability to perform post-translational modifications
such as glycosylation (Gemmill and Trimble, 1999;
Bretthauer and Castellino, 1999), fast and economic
growth, ease of scale-up to fermentation, and the op-
tion of expression of recombinant protein either intra-
cellularly or secreted into the culture medium
(Cereghino and Cregg, 2000) make the system ideal
for scFv production.
Here we report the successful expression of an
anti-CD33-scFv in P. pastoris strain KM71H, and
the demonstration of activity in interactions with tar-
get antigen CD33.2. Materials and methods
2.1. Bacteria and yeast strains
Bacterial and yeast strains used were Escherichia
coli XL1-Blue; recA1 endA1 gyrA96 thi-1 hsdR17
supE44 relA1 lac [FV proAB lacqZDM15 Tn10
(Tetr)] (Stratagene, La Jolla, CA, USA) and P. pas-
toris strain KM71H; aox1DARG4;arg4 (Invitrogen
Ltd, Paisley, UK).
2.2. Cell culture
Human leukaemic and T-helper cell lines (HL-60-
No. 98070106 and Jurkat E6.1-88042803, European
Collection of Cell Cultures, Salisbury, Wiltshire, UK)
were maintained in 90% RPMI-1640 (made bin
houseQ), 10% Foetal Bovine Serum (FBS) (Heat-inac-tivated, Gibco-BRL, Invitrogen) and 2 mM l-gluta-
mine (Gibco-BRL) at cell densities of 1–9105 and 3–
9105 cells/ml respectively, and incubated at 37 8C
with 5% CO2.
2.3. Cloning of anti-CD33-scFv
The gene encoding the anti-CD33-scFv was ampli-
fied using PCR from an existing construct encoding
an anti-CD33-scFv as part of a chimaeric T-cell re-
ceptor. This was previously generated in our labora-
tory (unpublished data) using an anti-CD33-mAb p67.
The variable domains of the genes were cloned from
the hybridoma using standard techniques (Nicholls et
al., 1993).
Primers were designed to facilitate insertion of the
construct into P. pastoris expression vector pPICZa
(Invitrogen), and to generate two constructs with a
complete and incomplete a-mating factor signal se-
quence cleavage site (hereafter referred to as CS and
INCS respectively), and a his-tag as shown in Table 1.
The primers used to generate the scFv constructs
were: 1) CSCD33SCFV5; ATATATCTCGAGA
AGAGAGAGGCTGAAGCAGATATCCAGCTCAC-




CTGTCACCAGTGT 2) INCSCD33SCFV5; ATAT
ATCTCGAGAAGAGAGATATCCAGCTCACTCAG-
AGT and CD33SCFVHIS. Regions complementary
to the scFv gene are underlined, and the remaining
regions were included to facilitate cloning. All pri-
mers were synthesised by Oswell, Southampton, UK.
Components of the PCR for generation of anti-CD33-
scFv constructs were 1X TaqPlus buffer, 2.5 units
TaqPlus (Stratagene), 50 AM each dNTP (Perkin
Elmer, Warrington, Cheshire, UK), 0.25 AM primers,
and 160 ng DNA template. Reaction conditions were:
94 8C–1 min, 1 cycle/94 8C–1 min, 60 8C–1 min,
72 8C–1 min, 25 cycles/72 8C–10 min, 1 cycle.
After PCR, the amplified scFv constructs were
ligated into pGEMTeasy (Promega, Madison, WI,
USA) and gel purified XhoI, NotI digested constructs
sub-cloned into the XhoI and NotI sites of the multi-
ple cloning site of pPICZa using a rapid ligation kit
(Roche, Lewes, East Sussex, UK). Recombinant
pPICZa-INCS/CS-CD33scFv-H was amplified in E.
Table 1
Diagrammatic representation of the anti-CD33-scFv gene expression constructs
Construct 1) CS–CD33scFv–H
Construct 2) INCS–CD33scFv–H











5V primers were designed to regenerate the cleavage site of the a-MF secretory signal sequence, such that the cleavage site of the signal sequence
would be flush with the N-terminus of the mature recombinant protein. Primers were also used to create complete and incomplete a-MF
cleavage sites, as indicated by the large oval. The adjoining black region between VH and VL indicates a (Gly4Ser)4 linker.
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ing to MWG Biotech (Milton Keynes, UK).
2.4. Transformation of P. pastoris
Competent cells of P. pastoris strain KM71H were
prepared and electroporated with 5 Ag SacI linearised
pPICZa-INCS/CS-CD33scFv-H DNA according to
the manual protocol for electroporation of P. pastoris
with the BIO-RAD Gene Pulser Xcellk Electropora-
tion system. Electroporation conditions wereC =25 AF,
PC=200 V, V=2.0 kV. Electroporated cells (50 Al)
were spread onto YPDS plates containing 100, 250,
500, and 1000 Ag/ml zeocin and incubated for 2–3
days at 30 8C. A number of colonies were then re-
streaked onto YPDS-zeocin plates to isolate single
colonies for PCR analysis and expression studies.
2.5. PCR analysis of positive transformants with
AOX1 primers
KM71H positive transformants were analysed for
the presence of the pPICZa-INCS/CS-CD33scFv-H
constructs using PCR with AOX1 primers (5VAOX1,
GACTGGTTCCAATTGACAAGC, 3VAOX1, GCA-
AATGGCATTCTGACATCC). To obtain template
DNA, single colonies from re-streaked YPDS-zeocin
plates were resuspended in 50 Al 1 mg/ml lyticase
(Sigma-Aldrich, Poole, Dorset, UK), incubated at
37 8C for 30 min, followed by boiling for 5 min. 2 Al
of lysed colonies were used for PCR analysis. PCRcomponents and conditions were as follows: 1 Taq
polymerase buffer II, 2 mM MgCl2, 0.2 mM each
dNTP, 1 Unit Taq polymerase (Perkin Elmer) and
0.5 AM each primer 5V and 3V AOX1, 94 8C–1 min,
1 cycle/94 8C–45 s, 60 8C–45 s, 72 8C–1.30 min,
30 cycles/72 8C–7 min, 1 cycle.
2.6. Screening for expression of anti-CD33-scFv
To screen for expression of anti-CD33-scFv, 25 ml
buffered glycerol complex medium with zeocin
(BMGY; 1% yeast extract, 2% peptone, 100 mM po-
tassium phosphate pH 6.0, 1.34% yeast nitrogen base
(YNB), 4105% biotin, 1% glycerol) were inoculat-
ed with PCR identified positive KM71H-pPICZa-CS/
INCS-CD33scFv-H transformants, and grown until an
OD600 of 20–40 was reached. Cells were then diluted 1
in 10 into 25 ml BMGY+1% Casamino acids, and
grown for a further 6–8 h at 30 8C with shaking of
250 rpm. These cultures were centrifuged at 5000g
and the pelleted cells resuspended in 25 ml buffered
methanol complex medium (BMMY; as BMGYexcept
that 1% glycerol was replaced with 0.5% methanol and
1% Casamino acids were added). Cultures were grown
for 96 h at 30 8C at 250 rpm, with addition of methanol
to a concentration of 0.5% v/v every 24 h. Samples
were taken at regular intervals for analysis of anti-
CD33-scFv expression.
Culture supernatant samples were analysed by
electrophoresis on 10% Nu-Page Bis–Tris gels (Invi-
trogen) followed by either Coomassie staining or
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ting was achieved using a semi-dry method with the
Trans-BlotR Semi-Dry electrophoretic transfer cell
(Bio-Rad, Hercules, CA, USA), with Bjerrum and
Schafer-Nielsen buffer (Bjerrum and Schafer-Nielsen,
1986) at 10 V for 30 min. Immunoprobing was carried
out using an anti-His-HRP antibody (BD Biosciences
Clontech, California, USA) as per manufacturer’s
protocol.
2.7. Purification of anti-CD33-scFv
To purify the anti-CD33-scFv from KM71H cul-
tures, affinity chromatography was used with a
HisTrapk HP kit using a 1 ml HisTrapk HP pre-
charged Ni Sepharosek high performance column
(Amersham Biosciences, Chalfont St. Giles, Bucks,
UK). The HisTrap column was linked to a peristaltic
pump P-1, and operated at a flow rate of 1 ml/min. To
prepare the sample, 10 ml of culture medium were
centrifuged at 5000g to remove the cells, and the
supernatant filtered through a 0.45 Am polyethersul-
fone filter (Sartorius, Surrey, UK). The manufacturer’s
optimisation protocol with a stepwise elution gradient
was used, to determine the ideal conditions for future
purifications of scFv. These were found to be; 1
phosphate buffer pH 7.4 (20 mM phosphate, 0.5 M
NaCl) with 100 mM and 300 mM imidazole for
equilibration and washes, and elution respectively.
Flow-through, washes and elutions were all collected
and stored at 20 8C.
2.8. N-terminal sequencing analysis
Purified anti-CD33-scFv was electrophoresed
using SDS-PAGE, and the separated proteins trans-
ferred to Sequi-Blotk polyvinylidene fluoride
(PVDF) membrane (Bio-Rad) using tris-glycine buff-
er (20 mM tris, 150 mM glycine, 10% methanol). The
semi-dry method used was as described in 2.6. After
transfer, the membrane was stained with Coomassie
stain (0.1% Coomassie Blue R-250, 40% methanol,
1% acetic acid) for 1 min, followed by destaining with
50% methanol until protein bands were clearly visible.
Protein bands corresponding to the expected MW of
the anti-CD33-scFv were excised and submitted for
N-terminal sequencing analysis. The first 10 amino
acids of purified CS and INCS anti-CD33-scFv weresequenced bin houseQ in the Protein Science Suite
using an Applied Biosystems Procise 492 protein
sequencer.
2.9. Analysis of cell binding
The binding ability of the anti-CD33-scFv to the
target antigen CD33, was analysed using CD33 posi-
tive HL-60 and CD33 negative Jurkat cell lines.
1106 cells in 100 Al 1phosphate buffered saline
(PBS) +2% FBS were incubated with a number of
antibodies as follows: isotype control IgG1n-FITC
(amount as per manufacturer’s protocol), anti-CD33-
FITC (20 ng) (BD Biosciences, San Jose, CA, USA),
anti-His-tag-FITC (660 ng) (Qiagen), and CS or INCS
anti-CD33-scFv (600 ng) followed by anti-His-tag-
FITC. Blocking experiments were performed using
HL-60 cells with unlabelled anti-CD33-Ab (120 ng)
(BD Biosciences) followed by CS or INCS anti-CD33-
scFv, and anti-His-tag-FITC. Cells were incubated
with antibody at room temperature for 30 min in the
dark, followed by two washes with 1 ml wash buffer
(1PBS, 2% FBS) after each antibody incubation,
with final resuspension of cells in 1 ml fixing solution
(1PBS, 1% paraformaldehyde). Using a flow cyt-
ometer (Becton Dickinson FACSCalibur), unlabelled
cells were used to place the cell population of interest
on scale, followed by gating of the isotype control
labelled cells into the first log phase, to adjust for
background fluorescence. The remaining samples
were then analysed for the presence of fluorescence.
2.10. Biacore studies
Binding of the anti-CD33-scFv to recombinant
soluble CD33 (ectodomain, amino acids 1–242 of
the mature protein) (rsCD33) also expressed by P.
pastoris (Emberson, 2002) was analysed with surface
plasmon resonance using a BIAcore 2000 system
(Biacore International SA, Stevenage, Herts, UK).
Binding studies were performed with both CS and
INCS scFv, by immobilizing N10,000RU scFv in 10
mM sodium acetate pH 5.0, onto a CM5 sensor chip
using the amine coupling method (Wizard procedure).
rsCD33, negative control glycoproteins (a 9 Ag/Al mix
of human transferrin, ribonuclease B, and human a1-
acid glycoprotein), and rsCD33 mixed with an anti-
CD33-Ab (Serotec, Oxford, UK) as a blocking exper-
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HBS-P buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl,
0.005% polysorbate 20 (v/v)) at a flow rate of 10 Al/
min at 25 8C. To determine the binding affinity of the
CS-anti-CD33-scFv, 750RU of the scFv in 10 mM
sodium acetate pH 5.0 was immobilised onto a CM5
sensor chip using the amine coupling method (Wizard
procedure). A range of concentrations of rsCD33 were
then passed over the immobilised Ab at a flow rate of
30 Al/min at 25 8C. ka, kd, and KD were determined
using BIAevaluation version 3.1 software, by fitting
data to a 1:1 Langmuir binding model (scFv). HBS-P
was used as running buffer, and 10 mM glycine–HCl
pH 2.5 was used as regeneration buffer, injected for
30 s at 10 Al/min. All reagents and buffers used were
from Biacore.3. Results
3.1. Anti-CD33-scFv cloning and transformation
Two constructs were generated using PCR to
encode an anti-CD33-scFv composed of a variable
heavy (VH) and variable light (VL) chain, linked by
(Gly4Ser)4 to allow spatial flexibility (Huston et al.,
1991). The two constructs differed in respect to the
N-terminus, whereby one construct had a complete
a-MF signal sequence cleavage site, and the other an
incomplete cleavage site, as indicated in Table 1.
The differing signal sequences were included to
accommodate the potential outcomes of Kex2 and
Ste13 processing of the recombinant scFv. Although
it has been suggested that the complete signal se-
quence is necessary for correct cleavage of the a-MF
(Sreekrishna et al., 1997; Raemaekers et al., 1999),
there are reports of incomplete cleavage by Ste13
leaving the Glu–Ala repeats at the N-terminus (Goda
et al., 2000; Almeida et al., 2001), and also effective
cleavage without the Glu–Ala repeats (Rosenfeld,
1999; Ruitenberg et al., 2001). These reports suggest
that the complete signal sequence is not always
necessary for correct cleavage, and also in some
cases leads to incorrect processing of the a-MF. At
the C-termini of both anti-CD33-scFv constructs,
stop codons and a (His6)2 tag were included via
PCR primers, to prevent the expression of the
(His)6 and c-myc tags of pPICZaA and replacethem with a single (His6)2 tag. This was done as
the (His6)2 tag was to be used for detection and
purification, and thus the c-myc tag and additional
amino acids between the c-myc and His-tag of
pPICZa were unnecessary.
The scFv constructs were successfully inserted
into the XhoI and NotI sites of pPICZaA, generating
the pPICZaA-CS-CD33scFv-H and pPICZaA-INCS-
CD33scFv-H plasmids, placing the constructs under
the control of the AOX1 promoter, for expression
and secretion of the ~30,000 Da anti-CD33-scFv.
After transformation of KM71H, PCR analysis of
zeocin-resistant transformants amplified a 1500 bp
DNA fragment corresponding to the 850 bp scFv con-
struct and flanking DNA up to the AOX1 primer sites
(Fig. 1). This confirmed the integration of pPICZaA-
CS-CD33scFv-H and pPICZaA-INCS-CD33scFv-H
respectively into 9/9 and 10/10 KM71H clones tested,
which were subsequently grown in cultures to screen
for expression of anti-CD33-scFv.
3.2. Screening for expression of anti-CD33-scFv
Initially, a number of KM71H-pPICZaA-CS/
INCS-CD33scFv-H (hereafter abbreviated as K-CS/
INCS-scFv) clones identified as positive transfor-
mants by PCR were screened for expression of the
anti-CD33-scFv using a protocol described by Gram
et al. (1998). Most clones tested expressed the anti-
CD33-scFv (data not shown), but further analysis
identified one clone of each construct as a high ex-
presser compared to all other clones screened. Time
course analyses of BMMY induction cultures of K-
CS-scFv clone 4 and K-INCS-scFv clone 4 were
performed and samples were analysed by SDS-
PAGE followed by Coomassie staining. The results
show that a protein with the expected MW of the anti-
CD33-scFv (ca. 30 kDa) was present in the culture
medium of K-CS/INCS-scFv, but not in that of the
parent strain KM71H (Fig. 2a). Further analysis with
western blotting/immunoprobing showed that an anti-
His-HRP Ab positively bound to protein bands of the
same MW in the scFv cultures but again not in the
parent strain culture (Fig. 2b). These results suggest
that the His-tagged anti-CD33-scFv was successfully
expressed in KM71H cultures.
Both Figs. 2a and b show that expression of the
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Fig. 1. PCR analysis of KM71H positive transformants using AOX1 primers. Whole PCR (20 Al) was electrophoresed on a 1% agarose gel at
12V/cm for 45–60 min. The gel on the left is a double gel with Lanes 1–8 and 9–16 corresponding to the upper and lower parts of the gel
respectively. Lanes 1, 9 and 17 show 0.5 Ag EHindIII and fX174HaeIII DNA markers, lanes 2–6 show PCR products from 5V and 3V AOX1
primer amplification of KM71H pPICZa-CS-CD33scFv-H clones 1–5, lanes 7, 8, 10–16 and 18 KM71H pPICZa-INCS-CD33scFv-H clones
1–10, and lane 19, control reaction with Pichia pastoris vector pPIC3.5.
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though the amount of anti-CD33-scFv was greater
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Fig. 2. (a) Time course analysis of BMMY KM71H-pPICZaA-CS/INCS
samples taken at 24, 48, 72, and 96 h of BMMY induction cultures were el
by Coomassie staining. Lane 1 shows 10 Al Bio-Rad kaleidoscope marker,
pPICZa-CS-CD33scFv-H clone 4, and KM71H-pPICZa-INCS-CD33scFv
of the parent strain KM71H. (b) Western blot/immunoprobing of time cours
cultures. 10 Al of culture supernatant from 0.5 ml samples taken at 24, 48, 7
10% Bis–Tris Nu-Page gel (Invitrogen) followed by transfer to nitrocellulo
(BD Biosciences Clontech). Lanes 1–4 and 5–8 show 24, 48, 72, and 9
KM71H-pPICZa-INCS-CD33scFv-H clone 4 respectively. Lane 9 showscomplete a-MF signal sequence, than from the cul-
ture of the construct with the incomplete a-MF
signal sequence.b
scFv
     1     2     3    4     5    6     7    8     9 
-CD33scFv-H cultures. 30 Al of culture supernatant from 0.5 ml
ectrophoresed on a 10% Bis–Tris Nu-Page gel (Invitrogen) followed
lanes 2–5 and 6–9 show 24, 48, 72, and 96 h samples from KM71H-
-H clone 4 respectively. Lane 10 shows a 96 h sample from a culture
e samples from BMMY KM71H-pPICZaA-CS/INCS-CD33scFv-H
2, and 96 h of BMMY induction cultures were electrophoresed on a
se, and immunoprobing with 1 in 10,000 anti-His-tag-HRP antibody
6 h samples from KM71H-pPICZa-CS-CD33scFv-H clone 4, and
a 96 h sample from a culture of the parent strain KM71H.
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After confirmation that His-tagged protein was
being expressed in K-CS/INCS-scFv cultures, protein
purification was performed in order that further anal-
ysis and characterisation of the His-tagged protein
identified in the time course analysis could be carried
out. Affinity chromatography was used with a
HisTrap column and protein eluted with 300 mM
imidazole.
Using this method of purification, approximately
95–100% of the protein was shown to bind to the Ni-
NTA agarose as seen from the lack of scFv in the
flow-through (lanes 3 and 7, Fig. 3), and the eluted
protein was relatively free of contaminants (lanes 5
and 9, Fig. 3), with a final yield of approximately 48
mg/l and 11 mg/l for CS-scFv and INCS-scFv respec-
tively. The purified CS-anti-CD33scFv has a MW of
~30,000 Da, consistent with the protein seen in the
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Fig. 3. Coomassie stained Nu-Page gel of purified anti-CD33-scFv.
Anti-CD33-scFv was purified on a Ni2+ column, and samples elec-
trophoresed on a Nu-Page 10% Bis–Tris gel, followed by Coomassie
staining. Lane 1: 10 Al Bio-Rad kaleidoscope marker. Lane 2: CS-
scFv, 20 Al, 96 h culture sample (cells removed). Lane 3: CS-scFv, 20
Al 6 ml flow-through concentrated to 0.5 ml. Lane 4: CS-scFv, 30
Al concentrated wash. Lane 5: CS-scFv, 1.5 Ag non-reduced purified
protein. Lane 6: INCS-scFv, 30 Al, 96 h culture sample (cells re-
moved). Lane 7: INCS-scFv, 20 Al 6 ml flow-through concentrated to
0.5 ml. Lane 8: INCS-scFv, 30 Al concentrated wash. Lane 9: INCS-
scFv, 1.5 Ag non-reduced purified protein. (The 100 kDa smear seen
in lane 9 was evident in some protein purification elutions. It has not
been identified, but may be proteins with histidine residues non-
specifically binding to the Ni-NTA agarose. Only pure INCS-anti-
CD33-scFv was used for further studies.)whereas the purified INCS-anti-CD33scFv, although
also migrating at the same MW, was present as a
doublet of bands seen in lane 9. These bands were of
a very similar MW and the relative intensity of each
was the same. Electrophoresis of the INCS-scFv on a
reducing gel, showed a similar doublet (data not
shown), indicating that the apparent difference in
size was due to MW rather than different disulphide
bonding patterns of mis-folded scFv. This heteroge-
neity in MW could be due to incorrect processing of
the a-MF signal sequence by Kex2. Alternatively or
in addition, differences in post-translational modifica-
tions such as glycosylation, may give rise to different
isoforms of the scFv, as the scFv and a-MF secretory
signal sequence contain one and three putative gly-
cosylation sites respectively.
3.4. N-terminal sequencing analysis
After successful identification of a His-tagged
protein in the MW range expected for the anti-
CD33-scFv in the KM71H expression cultures, sam-
ples of purified protein were subjected to N-terminal
sequencing analysis, to confirm the identity of the
proteins. It was apparent from the N-terminal se-
quencing data (Table 2) that the His-tagged proteins
identified in Fig. 2a and b were indeed the anti-
CD33-scFv. However, although the Kex2 protease
had cleaved the a-MF secretory signal sequence
from the CS-CD33scFv, the presence of extraneous
amino acids Glu–Ala–Glu–Ala at the N-terminus
indicated that Ste13 cleavage had not occurred. Ab-
errant processing of the aMF had also affected the
INCS-scFv as the sequencing data showed that the
upper band of the INCS-scFv doublet was most
likely to be incorrectly processed anti-CD33-scFv.
The amino acids are identical to the last 10 but
one of the a-MF secretory signal sequence (C-termi-
nus), showing that cleavage had occurred after Ile–
Ala (position 70, 71 of aMF) either by Kex2 or
another protease. Although the N-terminal sequenc-
ing data obtained did not extend into the scFv region
of the recombinant fusion protein, the MW and
positive binding of an anti-His-HRP Ab suggests
that the upper band of the doublet was INCS-scFv
with 11 amino acids from the C-terminus of aMF.
These extra amino acids are most likely responsible
for the increased MW seen upon migration in an
Table 2
N-terminal sequencing analysis data
1 A K E E G V S L E KINCS–Anti–
CD33–sc 
Fv10 cycles 2 D I Q L T Q S P S T
INCS–Anti–CD33–
scFv construct A K E E G V S L E K R – – – – D I Q L T Q S P S T
αMF secretory signal
(Last 15 amino acids) A K E E G V S L E K R
K E AS E AS Anti–CD33–scFv
CS–Anti–CD33–scFv 
construct 
A K E E G V S L E K R E A E A D I Q L T Q S P S T
CS–Anti–CD33–scFv
10 cycles E A E A D I Q L T Q
The table has been designed to radiate out from the middle. Therefore the middle row shows the last 15 amino acids of the a-MF, with the letters
in superscript corresponding to the Kex2 (K) and Ste13 (S) cleavage sites. The next two rows going outwards show the native sequence of the
N-terminus of the CS and INCS scFv constructs and difference in a-MF sequence. The next rows out show the sequencing data from the CS-
scFv (bottom row) and INCS-scFv (top two rows), with 1 and 2 corresponding to the upper and lower band respectively.
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correctly processed anti-CD33-scFv, as indicated by
the lack of extraneous amino acids at the N-terminus,
and 100% match with the native anti-CD33-scFv.
3.5. Cell binding analysis
To determine whether the anti-CD33-scFv ex-
pressed in P. pastoris was specific for target antigen
CD33, the INCS and CS scFv were incubated with
CD33 positive cells (HL-60) and a CD33 negative cell
line (Jurkat), followed by analysis with a flow cyt-
ometer. These cell lines were confirmed to be positive
and negative respectively for CD33 expression using
an FITC labelled anti-CD33-Ab. As shown in Fig.
4A,B, 99% of HL-60 cells fluoresced in the positive
M2 phase, whereas, as expected, only 2.2% of Jurkat
cells showed fluorescence in the positive M2 phase,
confirming that Jurkat cells express little or no CD33.
Analysis of HL-60 and Jurkat cells incubated with
CS/INCS anti-CD33-scFv followed by an anti-His-
FITC gave similar results, with 99% and 87% of
HL-60 cells fluorescing in the positive M2 phase, as
compared to 23.5% and 21% of Jurkat cells (CS-scFv
and INCS-scFv respectively). Although binding of the
anti-CD33-scFv to Jurkat cells was higher than that of
the anti-CD33-FITC-Ab (23.5% [CS] and 21%
[INCS] as compared to 2.2%), the anti-His-FITC-Ab
used as a secondary Ab to detect the scFv, bound
significantly to Jurkat cells (16.5%) when used alone,without the scFv. Therefore the apparent positive
binding of the anti-CD33-scFv to Jurkat cells is large-
ly accounted for by non-specific binding of the anti-
His-FITC Ab to Jurkat cells, rather than specific
binding of the scFv.
To confirm the specificity of the positive binding
observed with the anti-CD33-scFv to HL-60 cells, a
blocking experiment was performed whereby HL-60
cells were incubated with unlabelled anti-CD33-Ab,
to block available CD33 antigen sites. Cells were
then incubated with scFv, followed by anti-His-
FITC. Blocking with unlabelled anti-CD33-Ab re-
duced the percentage of cells fluorescing in the
positive M2 phase from 99% to 22.5% (CS-scFv)
and 87% to 10.5% (INCS-scFv), suggesting that the
binding of both CS and INCS anti-CD33-scFv to cell
surface antigen CD33 was specific.
3.6. Biacore analysis
Biacore studies were performed to assess the abil-
ity of the anti-CD33-scFv to bind to the target antigen
CD33, in a recombinant soluble form (rsCD33), also
expressed by P. pastoris (Emberson, 2002). Initial
binding studies performed with the scFv (INCS and
CS) showed binding to rsCD33, which was reduced
when using commercial monoclonal anti-CD33-Ab as
a blocking agent (INCS-scFv, Fig. 5a, similar data for
CS-scFv, not shown), suggesting that the scFv-
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Fig. 4. Binding of anti-CD33-scFv to CD33 positive and CD33 negative cell lines HL-60 and Jurkat. Panel A shows the binding of isotype
control (1), anti-CD33-FITC (2), CS-scFv (3), and INCS-scFv (4) antibodies to HL-60 cells, detected by FACS analysis. Panel B shows a plot of
the percentage of HL-60 and Jurkat cells in the positive M2 phase of the histogram after incubation with antibodies as stated, analysed using
FACS. Error bars represent Fone standard deviation.
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the scFv and rsCD33 were performed only with the
CS-scFv because of the heterogeneous nature of the
INCS-scFv. A range of concentrations of rsCD33 was
passed over 750RU of immobilized CS-scFv (Fig.
5b), and the data fitted to a Langmuir 1:1 model.
The ka and kd were determined to be 4.57103
M1 s1 and 1.6103 s1 respectively, with a
KD of 3.5107 M.4. Discussion
The aim of this study was to produce an anti-
CD33-scFv to use as a potential immunotherapeutic
agent for treatment of AML. P. pastoris strain
KM71H was used as it relies on the AOX2 gene
for production of alcohol oxidase, and thus grows
more slowly with methanol as a carbon source.
Strains with AOX1 deleted sometimes expresshigher levels of protein than wild-type strains, par-
ticularly in shake-flask cultures as observed for h-
galactosidase, invertase, and hepatitis surface antigen
(Tschopp et al., 1987a,b; Cregg et al., 1987) pre-
sumably because of lower oxygen demands. As it
was planned that the initial screening and expression
of scFv for further analysis would be carried out
using shake-flask cultures, KM71H seemed the ideal
strain to use. In addition, a protocol for scFv ex-
pression in P. pastoris used a Muts strain success-
fully (Gram et al., 1998).
Anti-CD33-scFv produced using constructs with
CS and INCS forms of the a-MF secretory signal
sequence (Table 1), were detectable in BMMY cul-
tures after 24 h, increasing in quantity up to 96
h (Fig. 2a,b). The amount of scFv produced in the
CS culture was clearly higher than from the INCS
culture. This higher level of scFv expression was not
clone-specific, since in a comparison of 10 clones of
each construct, CS clones consistently expressed
a 
b 
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Fig. 5. (a) Plot of interaction analysis between immobilized anti-CD33 scFv Ab (INCS) and rsCD33 alone and with Serotec anti-CD33 Ab. The
chart above corresponds to three separate sensorgrams that were obtained by passing rsCD33 or Serotec anti-CD33 Ab alone or in combination,
over immobilised INCS-anti-CD33 scFv. These were passed over the chip one after the other in the sequences as shown below with a
regeneration step in between to remove the bound analyte. The chart represents the increase in RU seen when each component is passed over the
chip, in the order as stated below. Interaction events order: Sensorgram 1: 5 Ag/ml Serotec anti-CD33 AbN5 Al regeneration buffer 10 mM
glycine–HCl pH 2.5 (RG)N6 Ag rsCD33N5 Al RGN6 Ag rsCD33+5 Ag/ml Serotec anti-CD33 AbN5 Al RGN6 Ag rsCD33N5 Al RG.
Sensorgram 2: 20 Ag/ml Serotec anti-CD33 AbN5 Al RGN40 Ag/ml Serotec anti-CD33 AbN5 Al RGN6 Ag rsCD33N6 Ag rsCD33+20 Ag/ml
Serotec anti-CD33 AbN5 Al RGN6 Ag rsCD33+40 Ag/ml Serotec anti-CD33 AbN5 Al RGN6 Ag rsCD33N5 Al RG. Sensorgram 3: 5 Ag/ml
negative control glycoproteins (mix of human transferrin, ribonuclease B, and human a1-acid glycoprotein)N5 Al RG. (b) Interaction of rsCD33
at concentrations 1220 nM, 1000 nM, 750 nM, 500 nM, 250 nM, and 50 nM (corresponding to curves from top to bottom), with immobilized
anti-CD33-CS-scFv to determine binding kinetics.
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plete and incomplete signal sequence fusions to the
scFv are processed by Kex2, it is possible that
inclusion of EAEA in the cleavage site (CS)
improves the accessibility of the site and therefore
facilitates faster processing.The His-tagged protein observed in the KM71H
cultures was confirmed as the anti-CD33-scFv by N-
terminal sequencing (Table 2). Although the scFv was
expressed using both the complete and incomplete
aMF, aberrant processing of the signal sequence
gave rise to three forms of the scFv. The CS construct
L.M. Emberson et al. / Journal of Immunological Methods 305 (2005) 135–151146produced only one form of anti-CD33-scFv, with
EAEA remaining at the N-terminus, whereas the
INCS construct produced two forms of anti-CD33-
scFv, one with 11 amino acids from the C-terminus of
the aMF, and another which was correctly processed
scFv.
Although the inclusion of EAEA repeats in the
aMF has been recommended to reduce steric hin-
drance from the folded protein (Sreekrishna and
Kropp, 1996), the CS-scFv was processed by Kex2
but not by Ste13, a problem also encountered with
other recombinant proteins expressed in P. pastoris
(Kim et al., 1997; Goda et al., 2000; Almeida et al.,
2001). A number of causes have been proposed for
the inefficient processing of the Glu–Ala repeats by
Ste13. One is that the amount of native Ste13 is
insufficient to cleave the Glu–Ala repeats from high-
ly expressed recombinant protein because there is
simply too much protein passing through the proces-
sing machinery of the cell (Harashima, 1994; Brake
et al., 1984). This problem has been overcome in
Saccharomyces cerevisiae by the inclusion of the
Ste13 gene on a multicopy plasmid (Barnes et al.,
1982). Another is that the tertiary structure of indi-
vidual proteins can be such that the Kex2 and/or
Ste13 cleavage sites become inaccessible to the pro-
teases necessary for cleavage of the a-MF secretion
signal (Cregg, 1999). A third is that glycosylation at
a site close to the N-terminus of a protein may also
obstruct the protease cleavage sites, as observed by
Weiss et al. (1998). Finally, it is thought that the
presence of certain amino acids, such as proline, in
close proximity to the Kex2 and Ste13 cleavage sites,
may inhibit the action of these proteases (Cereghino
and Cregg, 2000).
Of these potential inhibitors of Ste13 cleavage, it
seems most likely that the protein conformation of the
CS-scFv prevents cleavage by Ste13. Although the
CS-scFv is highly expressed, if there were not enough
Ste13 to process all the scFv correctly, a mixed pop-
ulation of correctly and incorrectly cleaved scFv
would be expected. This was the case with expression
of soybean root nodule phosphatase, where 60% of
protein retained EAEA, 30% EA, and 10% was cor-
rectly cleaved (Penheiter et al., 1998). However, N-
terminal sequencing clearly shows that Ste13 has not
processed any of the scFv. Also, the scFv only has one
putative glycosylation site, and as treatment of theCS-scFv with N-glycosidase-F did not cause any
reduction in MW (data not shown), it is unlikely
that glycosylation plays a role. Inhibition of Kex2
and/or Ste13 cleavage by protein conformation can
be overcome with the use of a pre rather than a pre-
pro signal sequence. The a-MF is a pre-pro signal
with the first 19 amino acids (pre) being cleaved while
the protein is in extended form by a signal peptidase
in the endoplasmic reticulum (ER) (Waters et al.,
1988). The pro-region is cleaved by Kex2 and Ste13
in the Golgi apparatus where the protein has taken on
its tertiary structure (Cereghino and Cregg, 2000;
Julius et al., 1984) potentially protecting the cleavage
sites from proteases Kex2 and Ste13. A pre signal
sequence is cleaved in the ER while in extended form,
eliminating any steric hindrance by the tertiary struc-
ture of the protein (Lyman and Schekman, 1996).
However, a pre-type sequence PHO1 used in P. pas-
toris (Payne et al., 1995) has also shown variability in
processing (Weiss et al., 1995; O’Donohue et al.,
1996), showing that use of a pre-type sequence is
only a solution in certain cases.
Variation in aMF processing was also observed
with the INCS-scFv, with similar amounts of each
of the two forms present. Cleavage of the a-MF at
position (amino acid) 70–72 has also been observed
with expression of aprotinin (Vedvick et al., 1991)
and phytohemagglutinin (PHA) (Raemaekers et al.,
1999), suggesting that specific protease activity is
responsible. Purification of His-tagged protein from
the cell pellet of INCS-scFv cultures showed that
both scFv forms were present at an intracellular
level (data not shown) suggesting that the incorrect
cleavage was occurring in the processing pathway,
rather than by an extracellular protease. Whether all
the INCS-scFv was initially processed this way, and
half subsequently cleaved by Kex2, or whether there
were two distinct processing pathways, is unclear.
Attempts to reduce the amount of protein being
expressed to allow for correct processing were per-
formed. However, growth of the induction cultures
at 25 8C and 22 8C had no affect on the processing
of aMF. Likewise, reduction of methanol concen-
tration from 0.5% to 0.4%, 0.3%, 0.2% and 0.1%
merely decreased expression of both forms overall.
Addition of the glycosylation inhibitor tunicamycin
to cultures had no affect on the processing, suggest-
ing that different glycosylation patterns of the pre-
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not shown). Steric hindrance of the folded protein
may play a role, since inclusion of EAEA in the
scFv construct (CS), and in constructs expressing
aprotinin (Vedvick et al., 1991) and PHA (Rae-
makers et al., 1999) resulted in correct cleavage
by Kex2. Since half of the scFv expressed from
INCS-scFv was correctly cleaved, we speculate that
there is a point in the folding pathway beyond
which the Kex2 site becomes inaccessible, but
prior to which the protein is in a conformation
amenable to cleavage. The rate of protein folding
and availability of Kex2 would be limiting factors
in this pathway, perhaps accounting for the two
forms of INCS-scFv. It is clear from our results
and those of others, that signal sequence processing
of P. pastoris expressed proteins is highly variable
and case specific, and therefore it is prudent to
generate constructs using different signal sequences
to accommodate the various outcomes of signal
sequence cleavage.
Despite the aberrant processing of the anti-CD33-
scFv, both the CS and INCS forms were found to be
functional, binding to the CD33 antigen in soluble
form and on the surface of cells. However, because of
the heterogeneity of the INCS-scFv, it was impossible
to determine whether one or both scFv forms
expressed from this construct, bound to CD33.
Attempts to separate the two scFv’s by ion exchange
chromatography have so far been unsuccessful.
Analysis of scFv interaction with native cell sur-
face CD33 on a human leukaemic cell line (HL-60)
showed binding to 99% (CS) and 87% (INCS) of
cells. This difference in binding of the CS-scFv and
INCS-scFv could be due to a concentration effect,
since although similar concentrations of scFv were
used, the INCS-scFv preparation contained the two
forms of the scFv. Only one of these may have been
binding to CD33, depending on the functionality of
the scFv with the 11 amino acid extension. Also, the
affinity of the scFv’s may be different, affecting the
binding to cell surface CD33. We were able to
determine the affinity of the CS-scFv using surface
plasmon resonance, but in the case of the INCS-scFv,
the heterogeneity prevented any reliable kinetic anal-
ysis of the interaction, and therefore, the affinity of
the scFvs could not be directly compared. Binding of
both the CS and INCS anti-CD33-scFv was signifi-cantly blocked by prior incubation with unlabelled
anti-CD33-Ab, reducing the number of cells in the
positive M2 phase by approximately 80%. Therefore,
both CS and INCS scFvs were shown to bind to the
target antigen CD33 on the surface of cells, which in
both cases could be blocked with monoclonal anti-
CD33-Ab, showing that the interaction was specific.
Studies using surface plasmon resonance provided
further evidence for the functionality and specificity
of the anti-CD33-scFvs, showing that both CS and
INCS scFvs bound specifically to rsCD33. These
results also confirmed that the inclusion of the C-
terminal His-tag had not affected the functionality of
the scFv in terms of binding to the target antigen.
This is important since studies have shown that the
inclusion and position of a His-tag on an scFv can
significantly affect antigen binding in some cases
(Goel et al., 2000a).
Kinetic analysis of the interaction between CD33
and the scFvs was only possible with the CS-scFv
because of the heterogeneous nature of the INCS-
scFv. Determination of the association and dissocia-
tion rate of the rsCD33-CS-scFv interaction showed
that the affinity of the scFv was fairly low but in a
range expected for monovalent scFvs. No kinetic
data is available for the parent anti-CD33-mAb, or
a Fab fragment of the Ab, and therefore at present no
comparison can be made with the affinity of the anti-
CD33-scFv. Although BIAcore was used to analyse
the kinetics of the anti-CD33-mAb and rsCD33 in-
teraction, attempts to immobilise rsCD33 have so far
been unsuccessful as the methods tested to date
affected the stability of rsCD33. This made it unsuit-
able for repeated interaction analyses, and therefore
kinetic analysis of the rsCD33 and anti-CD33-mAb
interaction has not been possible. The affinity of the
scFv may also be affected by the presence of the
additional EAEA residues at the N-terminus of the
scFv. Other groups have reported a decrease in af-
finity with scFv constructs that have extraneous
amino acids at the N-terminus, in comparison with
a normal scFv (Ping et al., 1993). Further work will
include refinement of the antigen binding assay and
also a comparison with an alternative binding assay
such as Scatchard analysis using FACS. This will be
performed with the CS-anti-CD33-scFv and the par-
ent anti-CD33-mAb, using CD33 positive cell line
HL-60, which should generate useful interaction ki-
L.M. Emberson et al. / Journal of Immunological Methods 305 (2005) 135–151148netics data. Also, internalisation studies will be per-
formed to determine whether the scFv is internalised
and the rate of internalisation. Since the parent Ab is
internalised into leukaemic cells (McGraw et al.,
1994), it is likely that the scFv will be also. The
importance of affinity of the scFv will partly be
determined by whether internalisation occurs, and
the rate of internalisation. The kinetic measurements
performed to date are intended as a benchmark by
which to determine whether future modifications to
the scFv, such as addition of a prosthetic group for
radiolabelling, will affect the affinity of the scFv,
rather than quantitative determination of the interac-
tion kinetics.
In summary, the anti-CD33-scFv was expressed
with a complete and an incomplete signal sequence
using P. pastoris, giving a reproducibly high yield,
which was easily purified to high purity, and found to
be functional and specific for the target antigen CD33.
They are therefore a potentially useful basis for the
development of immunotherapeutic reagents for the
diagnosis and treatment of leukaemia.Acknowledgements
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